Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2024-04-04 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - MYX 4 pages 14.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights for Mayne Pharma Group Limited. It provides specific information about securities that have ceased, including the number, reason for cessation, and updated issued capital figures. The document is a formal announcement to the ASX about changes in the company's securities, specifically the cessation of certain equity securities. It does not contain financial statements, management discussion, or detailed financial data. It is not a report but an official notification of securities cessation, which aligns with the category of Regulatory Filings (RNS) as it is a regulatory announcement that does not fit into more specific categories like capital changes or share issues. The document length is under 5,000 characters and is a direct announcement rather than a report or presentation.
2024-04-04 English
Notification regarding unquoted securities - MYX 5 pages 16.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance and conversion of unquoted options into ordinary fully paid shares. It includes specific information about the securities issued, dates, and quantities. This type of document is a formal announcement related to changes in the company's capital structure, specifically the issuance and conversion of securities. It is not a full financial report, earnings release, or management discussion. The content aligns with announcements about share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not merely a brief announcement or a regulatory filing fallback.
2024-03-25 English
Notification of cessation of securities - MYX 4 pages 14.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights for Mayne Pharma Group Limited. It provides specific information about securities that have ceased, including the number, reason for cessation, and dates. The document is a regulatory announcement related to changes in issued capital but does not report financial performance or detailed financial data. It is a formal notification to the ASX about securities ceasing to exist due to conditions not being met. This fits the category of a Share Issue/Capital Change announcement, as it relates to changes in the company's capital structure through cessation of securities.
2024-03-25 English
Ceasing to be a substantial holder 4 pages 132.2KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605 Notice of ceasing to be a substantial holder' and references Corporations Law Section 671B. It details changes in relevant interests of UBS Group AG and its related bodies corporate in the voting securities of Mayne Pharma Group Limited, including dates and quantities of securities bought and sold. This type of filing is a notification about changes in significant share ownership levels, specifically ceasing to be a substantial holder. It is not a financial report, earnings release, or management information. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is a substantive notification rather than a brief announcement or certification.
2024-03-17 English
Becoming a substantial holder 20 pages 322.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under Corporations Law Section 671B. It details the substantial shareholding of UBS Group AG and its related bodies corporate in Mayne Pharma Group Limited, including voting power, relevant interests, associates, and consideration paid. The document is regulatory in nature, reporting a change in significant share ownership levels. It is not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification, which is a notification of changes in significant share ownership levels crossing thresholds.
2024-03-11 English
Ceasing to be a substantial holder 4 pages 184.2KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and is a 'Notice of ceasing to be a substantial holder' under Corporations Law Section 671B. It details changes in relevant interests of UBS Group AG and its related bodies corporate in the voting securities of Mayne Pharma Group Limited, including dates and quantities of securities bought and sold. This type of filing is a notification of changes in significant share ownership levels, specifically the cessation of substantial shareholding. It is not a financial report, earnings release, or management report, but a regulatory notification about shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and detail confirm it is the actual notice, not just an announcement of a report.
2024-03-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.